IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v23y2022i4d10.1007_s10198-021-01383-0.html
   My bibliography  Save this article

A dynamic Markov model to assess the cost-effectiveness of the Kidney Team at Home intervention in The Netherlands

Author

Listed:
  • Steef Redeker

    (Erasmus Medical Center, Section of Medical Psychology and Psychotherapy, Department of Psychiatry, Postal Address)

  • Sohal Ismail

    (Erasmus Medical Center, Section of Medical Psychology and Psychotherapy, Department of Psychiatry, Postal Address)

  • Hester V. Eeren

    (Erasmus Medical Center, Section of Medical Psychology and Psychotherapy, Department of Psychiatry, Postal Address)

  • Emma K. Massey

    (Erasmus MC, Transplant Institute, Department of Internal Medicine)

  • Willem Weimar

    (Erasmus MC, Transplant Institute, Department of Internal Medicine)

  • Mark Oppe

    (Maths in Health)

  • Jan Busschbach

    (Erasmus Medical Center, Section of Medical Psychology and Psychotherapy, Department of Psychiatry, Postal Address)

Abstract

Objectives The Kidney Team at Home program is an educational intervention aimed at patients with chronic kidney disease to assist them in their choice for kidney replacement therapy. Previous studies have shown that the intervention results in an increase in knowledge and communication on kidney replacement therapy, and eventually in an increase in the number of living donor kidney transplantations. The study assesses the cost-effectiveness of the intervention compared to standard care. Methods A dynamic probabilistic Markov model was used to estimate the monetary and health benefits of the intervention in The Netherlands over 10 years. Data on costs and health-related quality of life were derived from the literature. Transition probabilities, prevalence, and incidence rates were calculated using a large national database. An optimistic and a pessimistic implementation scenario were compared to a base case scenario with standard care. Results In both the optimistic and pessimistic scenario, the intervention is cost-effective and dominant compared to standard care: savings were €108,681,985 and €51,770,060 and the benefits were 1382 and 695 QALYs, respectively. Conclusions The superior cost-effectiveness of the intervention is caused by the superior health effects and the reduction of costs associated with transplantation, and the relatively small incremental costs of the intervention. The favorable findings of this implementation project resulted in national uptake of the intervention in The Netherlands as of 2021. This is the first time a psychosocial intervention has been implemented as part of standard care in a kidney replacement therapy program worldwide.

Suggested Citation

  • Steef Redeker & Sohal Ismail & Hester V. Eeren & Emma K. Massey & Willem Weimar & Mark Oppe & Jan Busschbach, 2022. "A dynamic Markov model to assess the cost-effectiveness of the Kidney Team at Home intervention in The Netherlands," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(4), pages 597-606, June.
    • Handle: RePEc:spr:eujhec:v:23:y:2022:i:4:d:10.1007_s10198-021-01383-0
    DOI: 10.1007/s10198-021-01383-0
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s10198-021-01383-0
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s10198-021-01383-0?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. de Wit, G.Ardine & Ramsteijn, Paul G & de Charro, Frank Th, 1998. "Economic evaluation of end stage renal disease treatment," Health Policy, Elsevier, vol. 44(3), pages 215-232, June.
    2. Sigrid M Mohnen & Manon J M van Oosten & Jeanine Los & Martijn J H Leegte & Kitty J Jager & Marc H Hemmelder & Susan J J Logtenberg & Vianda S Stel & Leona Hakkaart-van Roijen & G Ardine de Wit, 2019. "Healthcare costs of patients on different renal replacement modalities – Analysis of Dutch health insurance claims data," PLOS ONE, Public Library of Science, vol. 14(8), pages 1-14, August.
    3. Melanie Wyld & Rachael Lisa Morton & Andrew Hayen & Kirsten Howard & Angela Claire Webster, 2012. "A Systematic Review and Meta-Analysis of Utility-Based Quality of Life in Chronic Kidney Disease Treatments," PLOS Medicine, Public Library of Science, vol. 9(9), pages 1-10, September.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Redeker, Steef & Massey, Emma K. & van Merweland, Ruben G. & Weimar, Willem & Ismail, Sohal Y. & Busschbach, Jan J.V., 2022. "Induced demand in kidney replacement therapy," Health Policy, Elsevier, vol. 126(10), pages 1062-1068.
    2. Kontodimopoulos, Nick & Niakas, Dimitris, 2008. "An estimate of lifelong costs and QALYs in renal replacement therapy based on patients' life expectancy," Health Policy, Elsevier, vol. 86(1), pages 85-96, April.
    3. Fabio Ferretti & Andrea Pozza & Maurilio Pallassini & Lorenzo Righi & Fulvia Marini & Sabrina Adami & Anna Coluccia, 2019. "Gender invariance of dignity in non-terminal elderly patients with chronic diseases: a multicentric study," Quality & Quantity: International Journal of Methodology, Springer, vol. 53(3), pages 1645-1656, May.
    4. Julia Widén & Magnus Ivarsson & Lovisa Schalin & Polina Vrouchou & Matthias Schwenkglenks & Olof Heimbürger & Zanfina Ademi & C. Simone Sutherland, 2020. "Cost-Effectiveness Analysis of Patiromer in Combination with Renin–Angiotensin–Aldosterone System Inhibitors for Chronic Kidney Disease in Sweden," PharmacoEconomics, Springer, vol. 38(7), pages 747-764, July.
    5. Baris Ata & Yichuan Ding & Stefanos Zenios, 2021. "An Achievable-Region-Based Approach for Kidney Allocation Policy Design with Endogenous Patient Choice," Manufacturing & Service Operations Management, INFORMS, vol. 23(1), pages 36-54, 1-2.
    6. Wolfgang C. Winkelmayer & Milton C. Weinstein & Murray A. Mittleman & Robert J. Glynn & Joseph S. Pliskin, 2002. "Health Economic Evaluations: The Special Case of End-Stage Renal Disease Treatment," Medical Decision Making, , vol. 22(5), pages 417-430, October.
    7. Wenjuan Fan & Yang Zong & Subodha Kumar, 2022. "Optimal treatment of chronic kidney disease with uncertainty in obtaining a transplantable kidney: an MDP based approach," Annals of Operations Research, Springer, vol. 316(1), pages 269-302, September.
    8. Mohsen Yaghoubi & Sonya Cressman & Louisa Edwards & Steven Shechter & Mary M. Doyle-Waters & Paul Keown & Ruth Sapir-Pichhadze & Stirling Bryan, 2023. "A Systematic Review of Kidney Transplantation Decision Modelling Studies," Applied Health Economics and Health Policy, Springer, vol. 21(1), pages 39-51, January.
    9. Sigrid M Mohnen & Manon J M van Oosten & Jeanine Los & Martijn J H Leegte & Kitty J Jager & Marc H Hemmelder & Susan J J Logtenberg & Vianda S Stel & Leona Hakkaart-van Roijen & G Ardine de Wit, 2019. "Healthcare costs of patients on different renal replacement modalities – Analysis of Dutch health insurance claims data," PLOS ONE, Public Library of Science, vol. 14(8), pages 1-14, August.
    10. Alexander V van Schoonhoven & Judith J Gout-Zwart & Marijke J S de Vries & Antoinette D I van Asselt & Evgeni Dvortsin & Pepijn Vemer & Job F M van Boven & Maarten J Postma, 2019. "Costs of clinical events in type 2 diabetes mellitus patients in the Netherlands: A systematic review," PLOS ONE, Public Library of Science, vol. 14(9), pages 1-22, September.
    11. Adedokun Oluwafemi Ojelabi & Afolabi Elijah Bamgboye & Jonathan Ling, 2019. "Preference-based measure of health-related quality of life and its determinants in sickle cell disease in Nigeria," PLOS ONE, Public Library of Science, vol. 14(11), pages 1-16, November.
    12. Pedro García-Martínez & Rafael Ballester-Arnal & Kavita Gandhi-Morar & Jesús Castro-Calvo & Vicente Gea-Caballero & Raúl Juárez-Vela & Carlos Saus-Ortega & Raimunda Montejano-Lozoya & Eva María Sosa-P, 2021. "Perceived Stress in Relation to Quality of Life and Resilience in Patients with Advanced Chronic Kidney Disease Undergoing Hemodialysis," IJERPH, MDPI, vol. 18(2), pages 1-10, January.
    13. Thomas W Ferguson & James Zacharias & Simon R Walker & David Collister & Claudio Rigatto & Navdeep Tangri & Paul Komenda, 2015. "An Economic Assessment Model of Rural and Remote Satellite Hemodialysis Units," PLOS ONE, Public Library of Science, vol. 10(8), pages 1-11, August.
    14. Bernadette Li & John Cairns & James Fotheringham & Rommel Ravanan, 2016. "Predicting hospital costs for patients receiving renal replacement therapy to inform an economic evaluation," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(6), pages 659-668, July.
    15. Afiatin & Levina Chandra Khoe & Erna Kristin & Lusiana Siti Masytoh & Eva Herlinawaty & Pitsaphun Werayingyong & Mardiati Nadjib & Sudigdo Sastroasmoro & Yot Teerawattananon, 2017. "Economic evaluation of policy options for dialysis in end-stage renal disease patients under the universal health coverage in Indonesia," PLOS ONE, Public Library of Science, vol. 12(5), pages 1-10, May.
    16. Trevor A. Ellison & Samantha Clark & Jonathan C. Hong & Kevin D. Frick & Dorry L. Segev, 2021. "Potential Unintended Consequences of National Infectious Disease Screening Strategies in Deceased Donor Kidney Transplantation: A Cost-Effectiveness Analysis," Applied Health Economics and Health Policy, Springer, vol. 19(3), pages 403-414, May.
    17. Braden Manns & David Meltzer & Ken Taub & Cam Donaldson, 2003. "Illustrating the impact of including future costs in economic evaluations: an application to end‐stage renal disease care," Health Economics, John Wiley & Sons, Ltd., vol. 12(11), pages 949-958, November.
    18. Joseph Menzin & Lisa Lines & Daniel Weiner & Peter Neumann & Christine Nichols & Lauren Rodriguez & Irene Agodoa & Tracy Mayne, 2011. "A Review of the Costs and Cost Effectiveness of Interventions in Chronic Kidney Disease," PharmacoEconomics, Springer, vol. 29(10), pages 839-861, October.
    19. Sergio Iannazzo & Michela Carsi & Silvia Chiroli, 2012. "A cost-utility analysis of cinacalcet in secondary hyperparathyroidism in five European countries," Applied Health Economics and Health Policy, Springer, vol. 10(2), pages 127-138, March.
    20. J. P. Sevilla & Daniel Tortorice & David Kantor & John Regan & Kinga H. Meszaros & Ekkehard C. Beck & Najida Begum & David E. Bloom, 2024. "Lifecycle model-based evaluation of infant 4CMenB vaccination in the UK," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 25(7), pages 1133-1146, September.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:23:y:2022:i:4:d:10.1007_s10198-021-01383-0. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.